Phase 1-2a Multicenter Dose-Ranging Study of Canfosfamide in Combination with Carboplatin and Paclitaxel as First-Line Therapy for Patients with Advanced Non-small Cell Lung Cancer
Lecia V. Sequist(Harvard University), Thomas J. Lynch(Nationwide Children's Hospital), Panos Fidias(Massachusetts General Hospital), Tatjana Kolevska(Kaiser Permanente Vallejo Medical Center), James Keck(Jackson Laboratory), Michael S. Rabin(Dana-Farber Cancer Institute), Glenn Mills(Louisiana State University Health Sciences Center New Orleans), D. Caldwell(Danville Community College), Mark S. Huberman(Beth Israel Deaconess Medical Center), Robert J. Belt(Unknown), Martin J. Edelman(Fox Chase Cancer Center), Marsha Jones, Howard A. Burris(Deaconess Hospital), Craig W. Englund(Inverness Research (United States)), Lisa Meng(Cytokinetics (United States)), Gail L. Brown(Palo Alto Institute), O.O. Melnyk(Bay Area Cancer Connections), Ralph V. Boccia(Center for Cancer and Blood Disorders), Jennifer S. Temel(Massachusetts General Hospital)
Cited by 19
Related Papers
Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.
|Journal of Clinical Oncology|1997|5.9k
Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2010|4.5k
Isolation of rare circulating tumour cells in cancer patients by microchip technology
|Nature|2007|3.5k
Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma With <i>EGFR</i> Mutations
|Journal of Clinical Oncology|2013|3.2k